No day without new discussions about cancer, however everyone at the European pharma industry agrees that the earlier a cancer disease is detected, the more favourable is the course of the disease and its outcome. Among women, breast cancer is the most common type of cancer, accounting for fifteen percent of cancer-related deaths. Breast cancer is usually detected through imaging methods like mammography, which women often considered uncomfortable. Therefore, the overall compliance in the population is low: Between 20 and 89 percent of women follow a screening invitation, depending on age and country. Scientists of the University Medical Center of Aachen have now developed a blood-based (Liquid Biopsy) test for detecting breast cancer and its pre-invasive stages. Considering the innovative potential of this easy-to-perform breast cancer test, PROvendis, one of the biggest patent marketing agencies in Germany, will present these novelty at the leading European fair for the diagnostic sector, BIO Europe 2016 in Cologne on November 7th - 9th 2016.